Evommune, Inc. (EVMN) Stock Forecast
EVMN analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.17 / 5 from 12 analysts
- Price target
- $22.33 average of analyst targets
- Upside to target
- +332.0% from the latest close
- Next earnings
- December 10, 2026 EPS estimate $-0.82
- 52-week range
- $5.17 – $31.57
EVMN analyst ratings
12 analystsNumber of analysts at each rating.
EVMN price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
EVMN earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.83 | −$1.02 | −$0.67 | −$8.07 | +89.7% | 11 |
| Current fiscal year (2026) | −$3.48 | −$5.53 | −$2.87 | −$11.22 | +69.0% | 12 |
| Next fiscal year (2027) | −$3.56 | −$4.37 | −$2.22 | −$3.48 | −2.3% | 12 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
EVMN revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | −100.0% | 8 |
| Current fiscal year (2026) | $0 | $0 | $0 | −100.0% | 8 |
| Next fiscal year (2027) | $250,000 | $0 | $2.0M | 0.0% | 8 |
EVMN EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
EVMN revenue: reported and forecast
EVMN EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.75 | −$0.81 | −$0.83 | −$0.84 | −$0.83 | +11.8% | 1 up · 5 down |
| Current fiscal year (2026) | −$2.79 | −$3.38 | −$3.40 | −$3.50 | −$3.48 | +24.7% | 0 up · 1 down |
| Next fiscal year (2027) | −$3.24 | −$3.36 | −$3.39 | −$3.54 | −$3.56 | +9.9% | 1 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
EVMN earnings surprises
Reported EPS vs the consensus estimate for the last 4 quarters; EVMN beat in 2 of 4.
What analysts expect from EVMN
12 analysts cover Evommune; their consensus rating is buy (4.17 on a 1–5 scale, where 5 is a strong buy). The average price target is $22.33, 332.0% above the latest close of $5.17. Analysts expect earnings of −$3.48 per share for 2026, +69.0% from a year earlier. For 2027 the average estimate is −$3.56 per share on revenue of $0.2 million. Evommune beat the EPS estimate in 2 of the last 4 quarters.
Related: EVMN income statement, EVMN key metrics, EVMN chart. See the EVMN stock overview for the latest quote and news.
EVMN forecast FAQ
What is Evommune's price target?
The average analyst price target for Evommune is $22.33, 332.0% above the latest close of $5.17.
Is Evommune a buy, hold or sell?
Of 12 analysts covering Evommune, 5 rate it a strong buy, 4 a buy, 3 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Evommune's EPS forecast?
Analysts forecast −$3.48 per share for 2026 (range −$5.53 to −$2.87); for 2027 the estimate is −$3.56.
When does Evommune report earnings?
Evommune is expected to report results for the quarter ending September 30, 2026 on December 10, 2026; the EPS estimate is $-0.82.
Does Evommune usually beat earnings estimates?
Evommune reported EPS at or above the analyst estimate in 2 of the last 4 quarters.